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ABSTRACT
Introduction Most cardiovascular disease (CVD)-related
events could be prevented or substantially delayed with
improved diet and lifestyle. Providing information on
structural vascular disease may improve CVD risk factor
management, but its impact on lifestyle change remains
unclear. This study aims to determine whether providing
visualisation and pictorial representation of structural
vascular disease (abdominal aortic calcification (AAC)) can
result in healthful diet and lifestyle change.
Methods and analysis This study, including men and
women aged 60–80 years, is a 12-week, two-arm,
multisite randomised controlled trial. At baseline, all
participants will have AAC assessed from a lateral spine
image captured using a bone densitometer. Participants
will then be randomised to receive their AAC results at
baseline (intervention group) or a usual care control group
that will receive their results at 12 weeks. All participants
will receive information about routinely assessed CVD risk
factors and standardised (video) diet and lifestyle advice
with three simple goals: (1) increase fruit and vegetable
(FV) intake by at least one serve per day, (2) improve other
aspects of the diet and (3) reduce sitting time and increase
physical activity. Clinical assessments will be performed at
baseline and 12 weeks.
Outcomes The primary outcome is a change in serum
carotenoid concentrations as an objective measure of FV
intake. The study design, procedures and treatment of data
will adhere to Standard Protocol Items for Randomized
Trials guidelines.
Ethics and dissemination Ethics approval for this study
has been granted by the Edith Cowan University and the
Deakin University Human Research Ethics Committees
(Project Numbers: 20513 HODGSON and 2019-220,
respectively). Results of this study will be published
in peer-reviewed academic journals and presented in
scientific meetings and conferences. Information regarding
consent, confidentiality, access to data, ancillary and post-
trial care and dissemination policy has been disclosed in
the participant information form.
Trial registration number Australian New Zealand
Clinical Trial Registry (ACTRN12618001087246).

Strengths and limitations of this study
►► To date, no studies have investigated whether pro-

viding visualisation and pictorial representation of
structural vascular disease in the abdominal aorta
(abdominal aortic calcification (AAC)) assessed on
scans from bone densitometers can result in greater
uptake and adherence to dietary and physical activity recommendations.
►► AAC from widely available bone densitometers is a
quick, cost-effective and reproducible method to visualise structural vascular disease.
►► Given the advantages of the imaging modality, this
test may be a useful tool to encourage individuals to
make healthful lifestyle choices and general practitioners to reinforce healthful lifestyle recommendations and encourage initiation and adherence to
cardiovascular medications.
►► A limitation is that this is a short-term 12-week randomised controlled trial and as such we cannot determine long-term dietary and lifestyle differences
between the control and intervention arms.

Introduction
Background and rationale
Cardiovascular diseases (CVDs) are the
leading cause of death. Globally, over 30% of
all deaths are attributable to CVDs, with the
majority of these due to either ischemic heart
disease (heart attack) or cerebrovascular
disease (stroke).1 In Australia, approximately
29% of all deaths have an underlying cause of
CVD.2 Often heart attacks and strokes are the
first clinical symptom of CVD with approximately 31% of first events being fatal.3
Furthermore, most survivors have substantial reductions in quality of life (QoL) due to
changes in functional capacity.
Poor lifestyle behaviours contribute to
the majority of CVD globally; improving

Radavelli-Bagatini S, et al. BMJ Open 2020;10:e036366. doi:10.1136/bmjopen-2019-036366

1

BMJ Open: first published as 10.1136/bmjopen-2019-036366 on 11 November 2020. Downloaded from http://bmjopen.bmj.com/ on December 3, 2020 at Edith Cowan University. Protected
by copyright.

Open access

diet, increasing physical activity and the cessation of
smoking can substantially reduce the burden of CVD.4
Even modest sustained lifestyle changes, such as adding
an extra serve of fruit and vegetable (FV) to the diet
or reducing sitting time, can lower CVD risk.5 Growing
evidence shows that a diet rich in FV (eg, two and five
daily serves of fruit and vegetable, respectively), can
lower the risk of CVD death, non-cardiovascular death
and death from all causes.6–9
Worldwide, over 5 million deaths per year are attributed
to diets low in FV;7 well over 10 million deaths per year
are attributed to lifestyle, including poor diet, physical
inactivity and smoking. Although there is an estimated
20% lower risk of CVD comparing high to low FV intake
(a 5% lower risk for each additional serving),6 most adults
do not meet the minimum recommended servings for
fruits (2 servings; ≥300 g/day) or vegetables (~5 servings; ≥375 g/day).10 11 In addition, 70%–80% of adults
fail to engage in the recommended amount of physical
activity.12 Improved diet and increased physical activity
would reduce the health expenditure associated with
chronic diseases.13 14
Current policy to prevent chronic disease is predicated
on detection of the traditional, recognised risk factors
such as altered blood lipids and elevated blood pressure (BP). However, new non-invasive tests that strongly
predict disease presence, development, progression
and outcome may lead to a paradigm shift in CVD risk
management and primary prevention of clinical disease.15
Vascular calcification can be used to assess atherosclerotic
vascular disease presence and burden. It can be measured
by CT in the coronary arteries (coronary artery calcification (CAC)) and X-ray in the abdominal aorta (abdominal aortic calcification (AAC)). The presence of any
CAC or any AAC provides a measurement of the amount
of calcium deposited in arteries, which are the surrogates for atherosclerosis, strongly predict CVD events
and substantially improve both sensitivity and specificity
to the identification of future CVD events.16–18 Furthermore, new calcified lesions (progression) are evidence of
active atherosclerosis likely to be related to poorer patient
outcomes.19 These methods represent a significant
advancement in CVD risk estimation and may be used in
primary prevention. However, due to cost and radiation
concerns, these tests are not used for community-based or
routine screening. In contrast, AAC assessed from lateral
spine images used to detect vertebral fractures from dual
energy X-ray absorptiometry (DXA) scans, offer an alternative and widely available method which has ultra-low
to negligible radiation (0.005 mSv), low cost and, consequently, can be used routinely in almost all clinical
populations.
Good evidence suggests that CAC screening improves
medication adherence and CVD risk factor management.20 21 However, there are limited data as to whether
CAC screening can motivate individuals towards beneficial behavioural or lifestyle changes to improve CVD
risk.21 To date, most of the available data in this area are
2

mixed21 and derived from observational studies, with only
a few randomised controlled trials (RCTs) conducted.21
Providing individuals with visualisation and pictorial
representation of structural vascular disease followed
by diet and lifestyle advice could stimulate protective
health behaviours. This approach is supported by well-
established models of health promotion and preventive behaviour.22–24 To date, no studies have investigated
whether providing individuals with visualisation and
pictorial representation of the presence and severity of
advanced structural vascular disease in the abdominal
aorta can improve both diet and physical activity, the
primary modifiable causes of CVD. In addition, AAC
scanning is a relatively new technique compared with
CAC scanning. It is important to examine within an RCT
framework the extent to which this technique can be used
as a tool to encourage healthy behaviour change and
monitor progression of CVD.
Objectives
The primary aim of this study is to investigate, for the first
time, whether providing individuals with visualisation and
pictorial representation of structural vascular disease presence and severity, assessed by widely available bone densitometers, can increase objective measures of FV intake
(serum carotenoids) after 12 weeks. Major secondary aims
are to evaluate whether providing visualisation and pictorial
representation of structural vascular disease will affect (1)
adherence to other dietary recommendations (eg, sodium,
fibre, whole grains, seeds and nuts); (2) adherence to
physical activity and sedentary behaviour (eg, sitting time)
recommendations; (2) CVD risk factors (such as BP, lipids
and glucose levels) and; (4) other health-related measures
(eg, gut health, physical function and mental health).
Trial design
This will be a 12-week, single-blind, two-arm, multisite RCT.
The study trial complies with the Standard Protocol Items
for Randomized Trials recommendations and guidelines for
protocols.25 This study will run in parallel at the Royal Perth
Hospital Medical Research Foundation, School of Medical
and Health Sciences at Edith Cowan University (Perth site)
and within the Institute for Physical Activity and Nutrition,
School of Exercise and Nutrition Sciences, Melbourne
Burwood Campus at Deakin University (Melbourne site).
Participants will be randomised (1:1) to either be provided
with their AAC results at baseline (intervention group)
or delayed until 12 weeks at the end of the RCT (control
group). Participants will be stratified according to the age
(above or below 70 years) and sex. A detailed process evaluation will be performed to assess the suitability, reliability
and implementation of all processes involved (Anokye R,
Radavelli-Bagatini S, Bondonno CP, et al. Process evaluation protocol for a multicentre, single-blind randomized
controlled trial: the MODEL study. Under review by the BMJ
Open (2019)).
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Methods
Participants, interventions and outcomes
Study settings
This study will be conducted in ambulant community-
dwelling Australian men and women, aged 60–80 years,
recruited from the general population in metropolitan
Perth and Melbourne and surrounding areas in Australia.
Eligibility criteria
A total of 200 participants (n=100 control group; n=100
intervention group) from Perth and Melbourne will
be recruited from the general population via media
advertisements and participant databases from previous
studies. A two-step screening process will be performed.
Eligibility will be assessed initially via a telephone
prescreen, followed by clinical assessments. An initial
telephone screening questionnaire will be used to determine the eligibility of potential participants based on the
inclusion/exclusion criteria. Volunteers who are eligible
and willing to proceed will be sent an information pack
and a clinic assessment visit will be scheduled for further
screening and testing.
Inclusion and exclusion criteria
Participants included will be ambulant men and women
aged 60–80 years. Exclusion criteria are (1) Body mass
index (BMI) ≥37 kg/m2 or BMI <18 kg/m2 or body weight
>125 kg; (2) type 1 diabetes; (3) type 2 diabetes if greater
than 10 years since diagnosis; (4) history of CVD events
including ischemic heart disease, cerebrovascular disease,
cardiomyopathy and peripheral arterial disease; (5) prior
CAC or coronary angiograms (within the last 2 years); (6)
use of anticoagulant therapy (warfarin); (7) those with
significant comorbidities, such as chronic kidney disease
(estimated glomerular filtration rate (eGFR) <30 mL/
min/1.73 m2), cancer (current) or heart failure (class
3 and 4)26; (8) systolic BP >160 mm Hg or diastolic BP
>100 mm Hg; (9) poor-image quality of the DXA scans
resulting in an inability to assess the AAC and (10) those
unable or unwilling to follow the study protocol. Eligible
participants will be asked to sign an informed consent
form prior to participation.
Assessments
The study flow chart is summarised in figure 1. At baseline, all participants will attend their screening appointment and baseline assessments, which includes their AAC
assessment from a lateral spine image captured using a
DXA densitometer. Participants will be then randomised
to either the control or the intervention group. Although
all participants will have their AAC scan performed at
baseline, only the intervention group will be provided
visualisation and pictorial representation of their AAC at
baseline. The control group will be provided this information at the end of the RCT (12 weeks). The schedule
of enrolment, interventions and assessments for the
study is shown in table 1. We will allow 3 weeks (lead-in
phase) for all baseline biochemistry and AAC results to

Figure 1 Study flow chart.

be available, before participants can be randomised and
attend the counselling visit. The lead-in phase will include
the following baseline assessments: (1) DXA scan for AAC
assessment as well as bone density (hip and spine) and
body composition; (2) anthropometry (body weight,
height, waist and hip circumference); (3) a fasting blood
sample for measurement of carotenoids (markers of
FV intake), glucose, creatinine (to estimate eGFR) and
lipids (cholesterol, triglycerides, high-
density lipoprotein (HDL) cholesterol); (4) urine sample for urinary
sodium, potassium and creatinine levels; (5) saliva test for
nitrate and nitrite concentrations; (6) clinic BP; (7) arterial stiffness using pulse wave analysis (PWA); (8) physical
activity assessed using ACTiGraph accelerometers and (9)
physical function assessments (handgrip strength (GS),
timed-up-and-go and gait speed). Questionnaires will be
used to capture information on other health and lifestyle
measures.
Baseline counselling visit
After being randomised to either the control or the intervention group, all participants will receive a 30-minute
counselling session visit (week 0), as outlined in table 2.
An unblinded counsellor trained in the need for impartiality will conduct all counselling sessions. To standardise
counselling, all participants will watch three educational
videos (~1, 3 and 7 min each, respectively), will receive
a booklet with dietary and lifestyle information and will
be provided with their baseline biochemistry (CVD risk
factor) results. This visit will run as follows:
1. The first video will contain information on the burden of CVD in Australia (from the Heart Foundation
Australia). This will be immediately followed by a second video containing information on blood vessel disease (atherosclerosis) and how this leads to CVD. For
the intervention group (AAC assessed), this video will
also include a short explanation of AAC and its link to
risk of heart attack and stroke. The video will conclude
by encouraging dietary and physical activity change to
reduce the risk of a heart attack or stroke.
2. Participants will be instructed to open an envelope
containing (1) results from their baseline risk factor
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Table 1 Study design
Enrolment

Allocation

Timepoint
Enrolment

Prescreen

Screening

Telephone prescreening

x

Informed consent

Baseline

12 weeks

x

Randomisation/allocation

x

Interventions
Intervention: Information on AAC

x

Control: Information on AAC

x

Dietary and lifestyle advice

x

x

Anthropometry

x

x

Dual energy X-ray absorptiometry

x

x

Blood, urine and saliva samples

x

x

Blood pressure

x

x

Arterial stiffness

x

x

Physical activity

x

x

Physical function
Questionnaires

x
x

x
x

Assessments

AAC, abdominal aortic calcification.

Table 2 Baseline counselling session chart flow
Intervention group

Estimated time

Control group

Estimated time

Video 1: National Heart
Foundation of Australia
Video 2: information on
cardiovascular disease and AAC

1 min

Video 1: National Heart
Foundation of Australia
Video 2: information on
cardiovascular disease

1 min

Letter with visual and pictorial
representation of their AAC scan
results
Biochemistry and blood pressure
results
Letter to the GP regarding the
study

5 min

Letter without AAC scan results 5 min
Biochemistry and blood
pressure results

Video 3: dietary and lifestyle
information

7 min

Video 3: dietary and lifestyle
information

7 min

 Further information

5 min

 Further information

5 min

3.5 min

►► Booklet on dietary and lifestyle

►► Booklet on dietary and

►► Frequently asked questions

►► FAQ

information

3 min

lifestyle information

(FAQ)

Face-to-face conversation with
investigator

5 min

Face-to-face conversation with
investigator

5 min

Postcounselling health status
questionnaire
Total time

3 min

Postcounselling health status
questionnaire
Total time

3 min

29.5 min

29 min

Information in italic represent the differences between intervention and control groups
AAC, abdominal aortic calcification; GP, general practitioner.
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assessments (both groups), including glucose and lipid
levels and blood pressure—any values outside the reference ranges will be flagged for general practitioner
(GP) follow-up; and (2) for the intervention (AAC assessed) group only, the results of their AAC scan will
include a graphic image with a pictorial representation
of the degree of calcification present and they will also
be provided with an explanatory results letter for their
GPs. Participants in both groups will be encouraged to
share all of their results with their GP.
3. The third video will then provide dietary and lifestyle
counselling, which will summarise usual care standard
dietary and lifestyle advice, with recommendations
based on the Australian Dietary Guidelines27 and the
recommendations on physical activity for older Australians,28 outlining three specific goals to be achieved
and maintained (1) to increase fresh fruit intake by at
least one serve per day (150 g/day) and increase vegetable intake by at least one serve per day (75 g/day);
(2) to improve other aspects of diet such as limiting
intakes of saturated and trans fats, salt, sugar and alcohol and increasing the intake of whole grains, seeds
and nuts; and (3) to increase physical activity and reduce sitting time. There will also be information on
other dietary and lifestyle recommendations including
serving sizes, food groups and alcohol intake (standard
drinks) based on the Australians Dietary Guidelines27
and The Heart Foundation Australia recommendations29; and key websites that may assist participants
to achieve desired changes. The video content will be
compiled in a hard copy booklet with additional detail
in relation to each of the three study goals, which will
also be provided to participants.
4. All participants will be provided with frequently asked
questions and will have a 5-minute face-to-face conversation with the investigator, who will answer any
questions raised. Participants will be asked to answer
a postcounselling questionnaire to assess perceived
health status.
At 12 weeks (end of RCT), all measurements performed
at baseline will be repeated. In addition, the counselling
sessions will be provided to both groups with the intervention group receiving the control group’s baseline counselling and vice versa (ie, participants in the control group
will receive the information about their level of advanced
blood vessel disease at 12 weeks). A personalised report
with the individual results and 12-week change will be
provided to all participants by mail within 3 months of
the end of the RCT.
Patient and public involvement
The study involved consumer representatives (n=2) in all
aspects of the study design providing input to the processes
and assessments of this research project. The Consumer
and Community Health Research Network, through
The Consumer and Community Involvement Coordinator (Mr Ben Horgan) based at Edith Cowan University, assisted our Involvement Strategy by supporting us to

find the most appropriate consumers for this work. The
consumers were women over the age of 65 years who have
attended five meetings, including four visits to the Medical
Research Foundation and one visit to the Bone Density
Department, over the last 12 months, prior to the start of
the study. The women contributed to the design of the
study, the informational material (results letter, handouts
and videos) which supported the intervention and gave
feedback about the burden of the intervention from the
patient’s perspective (including clinical assessments and
online questionnaires). The two women from the community involved in this research provided feedback on their
own clinical results and contributed to the dissemination
plan of the study by suggesting which information should
be provided and how it should be presented (graphic
representation of scan results, providing feedback on the
wording of all documents and questionnaires provided).
The consumers were provided with a AU$30 gift card for
each hour involved in the study. The information sheet
for the GPs was developed with feedback from five GPs at
two busy Perth Medical Clinics.
Outcome measures
Primary outcome measure
The primary outcome for this study will be circulating
total serum carotenoid concentrations as biomarkers of
FV intake.
Secondary outcomes
Secondary outcomes will affect changes on: (1) intake
of FV assessed using a validated semiquantitative food
frequency questionnaire (FFQ) developed by the Cancer
Council of Victoria, Australia30 31; (2) adherence to
other dietary recommendations including intake of
wholegrains and saturated and trans fats, salt, sugar and
alcohol assessed using the FFQ and other questionnaires;
(3) physical activity (minutes of moderate to vigorous,
number of steps per day, total minutes of physical activity,
sitting time) assessed using accelerometers along with the
Community Healthy Activities Model Program for Seniors
(CHAMPS) questionnaire; (4) CVD risk factors (including
lipids, blood glucose, blood pressure); (5) body weight
and body composition (including total body and regional
fat mass (kg) and body fat percentage, visceral adiposity
(kg), lean mass (kg) and bone mineral density of the hip
and spine (g/cm2)); (6) physical function (GS, timed-up-
and-go and gait speed); (7) health-related measures such
as sleep, smoking habits and knowledge and perception
of CVD; (8) oral nitrite and nitrate concentrations; (9)
medication and healthcare use and (10) psychological
measures (such as depression and anxiety disorders and
QoL).
Sample size
The required sample size for this study is 200 participants (n=100 control group; n=100 intervention group).
We expect a withdrawal rate of approximately 10% at 12
weeks. Rolling recruitment of participants will continue
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until the sample size of 200 is reached, which is estimated to take approximately 11 months. This sample
will provide 85% power, with a two-sided type 1 error rate
of alpha=0.05, to detect a 0.43 mg/L (~25%) difference
between control and intervention in total circulating
carotenoids at 12 weeks. This is based on a conservative
estimate of a SD of 1.0 mg/L.32 In addition, a sample size
of 100 participants in the intervention group will also
provide more than 80% power to detect a dose–response
effect (related to severity of AAC).
Participant allocation
Participants will be randomly allocated to either the
intervention or control group in a 1:1 ratio. ‘Based on
previous studies,33 34 we developed the inclusion criteria
in order to have at least 50% per group with evidence of
AAC’. The sequence of allocation will be generated using
Stata V.14 (StataCorp) and the user-written module called
‘ralloc’.35 Randomised blocks of size 4 will be created, so
that the randomisation is balanced at the completion of
assignment for each block. The randomisation will also
be stratified according to the age group (above or below
70 years) and sex. Within each strata, a sequential treatment code will be printed on paper in the order of treatment assignments. When the next available subject has
completed baseline assessments, an investigator who is
not involved in performing the intervention, data collection or data analysis will check the first available randomisation code in the sequence, reveal the treatment to be
assigned (intervention or control) and assign an appropriate code (A or B) next to the participants’ name on
a list of participants. Both the participant and the investigators responsible for the counselling session will be
unblinded throughout the trial. However, the researchers
performing the outcome assessments and data analysis
will be blinded to the treatments received until the end of
data analysis when the treatment codes will be revealed.
Data collection, management and analysis
Study investigators will have access to the data collection
forms and protocols using a secure shared drive. Participant information will be kept confidential with only the
study investigators having access to the data. Data will
be stored in password-
protected databases accessible
only by study investigators. Original backup files will be
kept in a separate electronic folder. The research will be
conducted within a research facility with electronic and
keycode access. All forms, protocols and questionnaires
used will be compiled in files, for easy accessibility. Checklists for clinic preparation and clinic days will be used to
ensure consistency. The following clinic assessments will
be performed.
DXA scans and AAC scoring
DXA scans will be performed at Gairdner Bone Densitometry Services, Sir Charles Gairdner Hospital, at the
Perth site, using the latest fan beam technology (Hologic
Horizon A densitometer). At the Deakin University site,
6

DXA scans will be performed using the Lunar iDXA, GE
Lunar, Madison, USA. The lateral spine image captured
will allow for assessment of AAC. Bone density of the hip
and spine as well as a whole body scans for body composition assessment will also be performed at the time of
AAC measurement. Focal AAC will be scored using a
semiquantitative scoring system (scored 0–24; AAC24).
This involves assessing the linear length of the vascular
calcification relative to the L1–L4 lumbar vertebra.34 36–39
Briefly, the length of the calcifications on the anterior
and posterior aortic walls is divided into four segments
corresponding to the lumbar vertebrae 1–4. For both the
anterior and posterior aortic walls, aortic calcification is
scored 0 if there is no calcification present, 1 if ≤one-third
of the aortic wall is calcified, 2 if >one-third to ≤two-thirds
is calcified or 3 if >two-thirds is calcified. As such, calcification corresponding to each of the four lumbar vertebra
can achieve a maximum of 2×3=6 points with a combined
maximum score of 24 points for L1–L4. All AAC scans will
be analysed by experts in densitometric imaging (John
Schousboe, University of Minnesota and/or Pawel Szulc,
University of Lyon—France). The actual participant’s
scan and pictorial representation of the presence and
extent of the AAC will be provided to the intervention
group at baseline and the control group at 12 weeks. The
whole-body DXA scan will be used to measure fat mass,
lean mass and visceral adipose tissue (VAT) mass. A technique for estimating VAT using DXA involves selecting
an area of interest with the superior border at the cranial
border of L2 and the inferior border at the caudal border
of L4. This has been shown to be well correlated with
CT-derived and MRI-derived measures of VAT (r2 >0.9).40
Anthropometry
Body weight will be measured using digital scales to
the nearest 0.1 kg with participants wearing lightweight
clothes and not wearing shoes. Height will be measured
using a wall-mounted stadiometer to the nearest 0.1 cm
while participants are not wearing shoes. BMI (kg/m2)
will then be calculated as weight in kilogram, divided
by height in metres squared. Waist circumference (cm)
will be measured using a Cescorf steel measuring tape,
in the standing position at the narrowest area between
the lateral lower rib and the iliac crest.41 Hip measurement (cm) will be taken at the largest circumference of
the lower abdomen. Waist and hip circumferences will be
measured three times and the median of each reported
as the score.
Human specimens (blood, urine and saliva)
Blood samples will be collected and standard biochemical analyses of fasting serum total cholesterol, HDL-
cholesterol and triglycerides will be performed.
Low-density lipoprotein cholesterol concentrations will
be calculated using the Friedewald formula.42 Glucose
and creatinine (eGFR) levels will be used to screen for
presence of diabetes and determine kidney function.
Estimated FV intake (primary outcome) will be assessed
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using circulating serum carotenoid concentrations. High-
performance liquid chromatography methodology will
be used to determine serum carotenoid concentrations of
β-carotene, lycopene, α-carotene, β-cryptoxanthin, lutein
and zeaxanthin, as previously described.32 43 Serum carotenoids will be measured to assess FV intake, as FV are the
primary contributors to intake of carotenoids (such as αcarotene, β-carotene and lutein/zeaxanthin)44 and they
are recognised and commonly used biomarkers of FV
consumption.45 A 24-hour urine sample will be collected
in a sterile container provided. Urine samples will be
analysed for electrolytes including creatinine, sodium
and potassium. Saliva samples will be obtained to assess
salivary nitrate and nitrite concentrations and to determine the nitrate to nitrite reduction ratio.46 Participants
will be asked to sit quietly for 5 min while spitting into a
sterile specimen container. Saliva aliquots will be stored
at −80°C.

hand will be recorded as the highest of three attempts50
using a handheld dynamometer (Jamar Hydraulic Hand
Grip Dynamometer; Nottinghamshire, UK); (2) timed
up-and-go will be used to assess mobility, in which participants are timed (using a stopwatch) raising from a seated
position on a standard arm chair (45 cm) and asked to
walk at a comfortable and safe pace to a 3 m mark, turning
to return to their seated position on the chair with their
back touching the backrest of the chair.51 Participants will
be instructed to perform one practice trial before the
next two recorded attempts with the fastest time reported
and (3) gait speed in which participants will be timed
while walking at their usual pace over 4 m. Participants
will be instructed to walk at their usual pace over 8 m and
the time taken to walk the middle 4 m will be recorded on
a stopwatch to determine gait speed. Time taken to walk
the first and last 2 m of the course is excluded due to the
acceleration and deceleration phases, respectively.52

Clinic BP
Clinic BP will be assessed using a validated automatic
BP monitor. After participants have rested for 5 min in a
supine position, BP measurements will be assessed on five
occasions at 1 min intervals. The first measurement will
be discarded and the mean of the final four readings will
be calculated.

Questionnaires
Dietary intake will be assessed using a semiquantitative FFQ developed by the Cancer Council of Victoria,
Australia,31 administered by one of the study investigators
at each clinic visit. A link for a series of questionnaires to
be completed online, which have been used widely in clinical research including by our team, will be sent to participants at baseline and 12 weeks, as described below: (1)
Demographic and Lifestyle Questionnaire: will be used
to assess demographic and lifestyle information, smoking
habits and knowledge and perception of CVD risk; (2)
Beverages Questionnaire: a self-
administered beverage
questionnaire will be used to estimate the average daily
or weekly intake of beverages across 12 types of drinks
(tea, herbal tea, coffee, decaffeinated coffee, chocolate,
fruit juice, soft drinks, diet drinks, dairy milk, non-dairy
milk, fruit and/or vegetable smoothies and water) as well
as alcohol intake (beer, red and white wine and spirits);
(3) CHAMPS questionnaire: a self-reported measure of
physical activity to estimate weekly (4 weeks timeframe)
frequency of participation (types) and energy expenditure (intensity levels) of physical activities in older
adults53; (4) Longitudinal Ageing Study Amsterdam questionnaire will be used to assess sedentary behaviour54;
(5) well-being and QoL will be assessed by the Medical
Outcome Study Short Form‐36 (SF‐36)55 and the Sub-
optimal Health Status questionnaire (SHSQ-25) status.56
SF36 includes eight domains of physical functioning,
role‐physical, bodily pain, general health, vitality, social
functioning, role‐emotional and mental health, which
are combined to form two key domains—physical functioning and mental health. SHSQ-25 is composed of 25
items and includes five subscales: fatigue, the cardiovascular system, the digestive tract, the immune system and
mental status; (6) Depression Anxiety Stress Scales-21:
is a self-report questionnaire designed to measure the
negative sensitive conditions of depression, anxiety and
stress; (7) Bowel Symptoms Questionnaire will be used
to investigate bowel habits along with the Bristol stool

Pulse wave analysis
PWA will be used to assess central aortic blood pressure
and stiffness (augmentation index, %),47 using the Sphygmocor Xcel device as described previously.48
Actigraphy
Accelerometry (ActiGraph GT3X, Pensacola, Florida,
USA) will be used at baseline (lead-
in-
phase) and 12
weeks, each for 7 consecutive days to investigate average
daily physical activity levels. Of note, the ActiGraph
device is the most widely used accelerometer in physical
activity research.49 Briefly, participants will be instructed
to wear the accelerometer over the right hip secured with
an elastic band while awake and during sleep (if possible)
and to remove the accelerometer when doing water activities. Accelerometers are ideal for determining physical
activity as they require minimal input from the participant over the collection period. To improve the accuracy
of our data, participants will also be asked to report any
times the monitor is removed using a concurrent daily
Activity Monitor Record/Nap Time Questionnaire during
the 7-day period. Physical activity outcome measures will
include moderate-to-vigorous physical activity (min/day),
total physical activity (min/day), sedentary time (min/
day) and daily step count (steps/day). These measures
will be quantified using the ActiLife Data Analysis Software provided by the manufacturer (ActiLife V.6.13.4,
Pensacola, Florida, USA).
Muscle strength and physical function
Muscle strength and physical function will be assessed by
three tests: (1) GS of both the dominant and non-dominant
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chart, a medical tool designed to assess stool consistency
(types 1 and 2 indicate constipation, types 3 and 4 are
the ‘ideal stools’ and types 5–7 suggest diarrhoea or bowel
urgency)57; (8) Readiness to Change and Wellbeing
Questionnaire is a behaviour modification questionnaire
(developed by the WorkStrong program, University of
California system wide program) which focuses on individuals’ readiness to change over seven different aspects:
life satisfaction, energy, weight, exercise, nutrition, health
and stress and mental health; (9) Pittsburgh Sleep Quality
Index: a questionnaire used to measure the quality and
patterns of sleep in older adults58; (10) current medication use: a comprehensive list of medications (which will
be cross-checked with bottles/packets of tablets concomitantly) and; (11) Health Care Use Questionnaire: will
be used to investigate any procedures or further medical
tests requested by GPs as well as visits to healthcare
professionals. Online questionnaires will be checked for
completeness prior to each clinic visit and any missing
questions will be completed at the clinic visit. The ‘Life’s
simple 7’ metric from the American Heart Association
will be used to assess participant’s ‘ideal’ cardiovascular
health. This considers seven risk factors that people can
improve through lifestyle changes: quit smoking, increase
their physical activity, achieve a healthy weight, eat a
healthy diet, reduce their blood glucose, control their
cholesterol and manage their blood pressure.59
Other forms
Participants will be asked to complete a 24-hour urine
record form along with the Flavonoids questionnaire,
which will be used to estimate the consumption of foods
and beverages rich in flavan-3-ols in the 24 hours prior to
their visit. The number of serves consumed (0, 1, 2, 3 or
4+) across 22 foods and beverages will be assessed.
A postcounselling health status questionnaire will
be used to assess the participants’ perceptions and
intentions towards CVD risk and to the study proposed
changes, immediately after receiving information on
CVD and diet and lifestyle (counselling visit). The
questions aim to explore participants perceived susceptibility and severity60 61 in relation to the heart disease
video content. It also explores the response efficacy, self-
efficacy and their intentions (Likert scale: 1=strongly
disagree; 5=strongly agree) towards the three main study
goals.
Data management
The majority of data will be electronic and directly sent
to the Qualtrics database. Online questionnaires have
been designed with mandatory answers required to avoid
missing data. Nevertheless, these data will be checked by
an investigator prior to clinic day. Data from clinic assessments and paper questionnaires will be entered into
individual spreadsheets by a study investigator. A representative number of files will be selected by a different
investigator, who will check whether the information
matches that in the electronic spreadsheets.
8

Statistical methods
Statistical analysis will be performed using IBM SPSS
(V.25; IBM)62 and Stata V.14 (StataCorp). Descriptive
statistics will be used to describe the individuals characteristics at baseline. The primary analysis will be
performed on a modified intention-
to-
treat basis with
the population defined as those randomised participants
for whom there are baseline measurements. Data will
be assessed for outliers and normality prior to analysis
and log-transformed if necessary. Baseline and 12-week
values for outcome measures and between-group differences will be presented as means and SDs. The treatment
effect for each of the outcomes will be analysed using
generalised linear mixed models to examine the baseline
adjusted differences between intervention and control in
12-week values. In addition to including visit and treatment group as fixed effects in each model, an interaction
term between visit and treatment groups will be included
and used to determine the effect of the intervention.
The randomisation site and the individual will both be
included in the models as random effects to account for
clustering. A per-protocol analysis will be performed as
a secondary analysis using only those participants with
measures recorded at baseline and 12 weeks. An overall
two-sided type-1 error rate of p<0.05 will be used to assess
statistical significance for all hypothesis testing.
Monitoring
Participants will be monitored for any adverse events
during clinical assessments by the study investigators
which have been detailed in the participant information form. The study clinical coordinator will oversee all
aspects of participant management where required.
Ethics and dissemination
Ethics approval for this study has been granted by the Edith
Cowan University Human Research Ethics Committee
(HREC) (Project number: 20513 HODGSON) and
Deakin University HREC (Project number: 2019-220).
Results of this study will be published in peer-reviewed
academic journals and presented in scientific meetings
and conferences. Information regarding consent, confidentiality, access to data, ancillary and post-trial care and
dissemination policy have been disclosed in the participant information form.
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